Insurance Coverage Differs by Demographics, Cancer Type
the Cancer Therapy Advisor take:
Patient demographics and cancer type are major contributing factors for the variation in rates of insurance coverage, according to an article published online in the journal Cancer.
Participants of this study included 688,794 patients between the ages of 18 to 64 years with a diagnosis of one of the top 25 incident cancers between 2007 and 2010 in the Surveillance, Epidemiology, and End Results (SEER) database.
The patients were analyzed based on characteristics, such as age, race, sex, marital status, residency, and county-level demographics (e.g., percent poverty level). The individual’s insurance status was determined to be non-Medicaid insurance, Medicaid coverage, or no insurance.
Results showed nonwhite, younger age males, unmarried, residence in counties with higher levels of poverty, and rural residence were associated with being uninsured versus having non-Medicaid insurance (all P<0.001).
Patients with prostate cancer, melanoma, and thyroid cancer had the highest non-Medicaid insurance rates (92.3%, 92.5%, and 89.5%, respectively), while patients with cervical, liver, and stomach cancer had the lowest rates of non-Medicaid insurance (64.2%, 67.9%, 70.9%, respectively;P<0.001).
The majority of uninsured patients reported cases of lung cancer (14.9%), colorectal cancer (12.1%), and breast cancer (10.2%) (all P<0.001).
Lung cancer was found to cause the majority of cancer mortality across all insurance categories.
Patient demographics and cancer type are major contributing factors for the variation in rates of insurance coverage.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Calcium and Cancer
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer
- Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma
- Cabozantinib Effective as Salvage Therapy in Thyroid Cancer
- Everolimus Maintains Quality of Life in Neuroendocrine Tumors
- High Dose Vitamin B Supplements Should Not Be Taken for Lung Cancer Prevention
- Telomere Length May Predict Renal Cell Carcinoma Risk in Patients with VHL
- Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse
- Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection